Warren Raymond

ORCID: 0000-0002-2537-0070
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Systemic Lupus Erythematosus Research
  • Vasculitis and related conditions
  • Rheumatoid Arthritis Research and Therapies
  • Renal Diseases and Glomerulopathies
  • Hip and Femur Fractures
  • Atherosclerosis and Cardiovascular Diseases
  • Gout, Hyperuricemia, Uric Acid
  • Spondyloarthritis Studies and Treatments
  • Musculoskeletal Disorders and Rehabilitation
  • Urticaria and Related Conditions
  • Bone health and osteoporosis research
  • Platelet Disorders and Treatments
  • Otitis Media and Relapsing Polychondritis
  • Systemic Sclerosis and Related Diseases
  • Cytokine Signaling Pathways and Interactions
  • Coagulation, Bradykinin, Polyphosphates, and Angioedema
  • Chronic Disease Management Strategies
  • Orthopedic Infections and Treatments
  • Autoimmune and Inflammatory Disorders Research
  • Blood Coagulation and Thrombosis Mechanisms
  • Immunodeficiency and Autoimmune Disorders
  • Health Systems, Economic Evaluations, Quality of Life
  • Inflammatory Bowel Disease
  • Medical Coding and Health Information
  • Case Reports on Hematomas

The University of Western Australia
2016-2023

Edith Cowan University
2020-2023

Sir Charles Gairdner Hospital
2014-2022

Osborne Park Hospital
2022

Center for Rheumatology
2021

Royal Perth Hospital
2019

North Metropolitan Health Service
2018-2019

To assess the impact of achieving Lupus Low Disease Activity State ≥50% time (LLDAS-50) on damage accrual and mortality in an inception cohort patients with systemic lupus erythematosus (SLE).We used data from Tromsø Cohort, a longitudinal population-based study all SLE 2 northernmost counties Norway. LLDAS was defined as 1) Systemic Erythematosus Index 2000 score ≤4, no activity major organ systems, 2) new features disease activity, 3) current therapy prednisolone (or equivalent) dosage...

10.1002/acr.23867 article EN Arthritis Care & Research 2019-03-01

Abstract Background Poor sleep is common after stroke, and data regarding its effect on rehabilitation outcomes are limited. Controversial evidence was found concerning the of sedatives improving quality in poor sleepers stroke. Aim To assess prevalence post‐stroke patients outcomes. Method A total 104 stroke from two major units Western Australia enrolled. Sleep assessed using Pittsburgh Quality Indexes at baseline The main outcome measures were Functional Independence Measure (FIM) change...

10.1111/imj.14372 article EN Internal Medicine Journal 2019-05-21

Abstract Background Before the role of shear wave elastography (SWE) and B mode ultrasound (US) in diagnosis different forms idiopathic inflammatory myopathies (IIM) can be investigated, normative data is required. This study aimed to describe then compare SWE metrics muscles healthy controls patients with IIM. Methods Twenty nine adult 10 IIM (5 inclusion body myositis 5 necrotising autoimmune myopathy) underwent a full clinical examination, laboratory investigations, US measurements...

10.1186/s12891-021-04424-0 article EN cc-by BMC Musculoskeletal Disorders 2021-06-12

The interleukin 17 (IL-17) cytokine family is involved in a number of chronic inflammatory diseases. In spite contradictory findings and lack causality clinical studies, IL-17 inhibition for systemic lupus erythematosus (SLE) has regained attention as potential therapeutic pathway, after demonstrating disease-modifying capabilities ankylosing spondylitis. We investigated the associations A (IL-17A) patients with SLE.

10.5152/eurjrheum.2017.16059 article EN cc-by-nc European Journal of Rheumatology 2017-03-01

To investigate the impact of uric acid (UA) levels on cardiovascular disease and mortality at a population level. Prospective analysis baseline serum UA measurement 15 year follow-up data from Busselton Health Survey (n = 4,173), stratified by existence or absence disease. Outcomes were ascertained state-wide hospital discharge registries. Cox regression produced adjusted hazard ratios (HR) for level as continuous categorical (low, medium, high) predictor events (CVE) mortality. Gout was...

10.1186/s12872-016-0421-1 article EN cc-by BMC Cardiovascular Disorders 2016-12-01

Objective. To compare the long-term prevalence, incidence, and outcomes of vertebral fracture (VF) between ankylosing spondylitis (AS) patients matched controls, including role extraarticular manifestations (EAM) osteoporosis. Methods. This was a statewide observational study using linked health data for 2321 with AS 22,976 controls presenting to hospital from 1980 2015. Data were analyzed incidence rates (per 1000 person-yrs) ratios (IRR), multivariable Cox proportional hazards regression,...

10.3899/jrheum.190675 article EN The Journal of Rheumatology 2020-02-15

Cardiovascular disease is the most common cause of death in people with gout. Acute inflammation, which a characteristic gout, may have mechanistic role major adverse cardiovascular events (MACEs). We aimed to examine relationship between admissions hospital acute gout and MACEs large population-based data set.We extracted from Hospital Morbidity Data Collection Death Registrations Western Australian Rheumatic Disease Epidemiology Registry. identified patients admitted incident who had or...

10.1002/acr2.11540 article EN cc-by-nc-nd ACR Open Rheumatology 2023-05-11

A high body mass index is known to adversely affect antitumor necrosis factor-alpha trough levels and secondary loss of response (SLOR) in patients with Crohn's disease. We hypothesize that adiposity negatively these outcomes aimed determine if this relationship exists.We performed a retrospective cross-sectional study 69 disease from two tertiary inflammatory bowel centers between February 1, 2015, June 30, 2018. Primary responders infliximab (IFX) or adalimumab (ADA) who had level within 6...

10.14309/ctg.0000000000000233 article EN cc-by-nc-nd Clinical and Translational Gastroenterology 2020-09-01

Background . A geriatric evaluation and management unit (GEM) manages elderly inpatients with functional impairments. There is a paucity of literature on frailty whether this impacts rehabilitation outcomes. Objectives To examine score (FS) as predictor gain, resource utilisation, destinations for GEM patients. Methods single centre prospective case study design. Participants (<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"...

10.1155/2014/357857 article EN cc-by Current Gerontology and Geriatrics Research 2014-01-01

Aim To assess the effect of age‐adjusted Charlson Comorbidity Index ( CCI ) score on Functional Independence Measure FIM gain in older rehabilitation patients. Methods This prospective cohort study observed 306 patients admitted to a secondary hospital between February and April 2015. Groups were compared using cut‐offs ≤4, 5–6 ≥ 7. Results Complete data available for 280 The mean was 5.59 ± 1.96. An ≤4 correlated with higher scores at admission P = 0.015, discharge 0.002, but not greater...

10.1111/ajag.12351 article EN Australasian Journal on Ageing 2016-09-12

Objective In SLE, smoking increases the burden of cutaneous disease and organ damage, leads to premature mortality. However, effect on manifestations cytokine levels patients with SLE is unclear. This study compared characteristics across status, determined association serum levels. Method A cross-sectional (n=99) during a research visit in which status was ascertained. Smoking classification criteria (American College Rheumatology Classification Criteria for (ACR97)), activity (SLE Disease...

10.1136/lupus-2021-000537 article EN cc-by-nc Lupus Science & Medicine 2021-10-01

Abstract Objectives With sparse data available, we investigated mortality and risk factors in adults with IgA vasculitis (IgAV). Methods This was an observational population-based cohort study using state-wide linked longitudinal health for hospitalized IgAV (n = 267) matched comparators 1080) between 1980 2015. Charlson comorbidity index (CCI) serious infections (SIs) were recorded over extensive lookback period prior to diagnosis. Date causes of death extracted from the Western Australia...

10.1093/rheumatology/keab312 article EN Lara D. Veeken 2021-03-26

Objective. To examine mortality rates in hospitalized patients with ankylosing spondylitis (AS) and the association of extraarticular manifestations (EAMs) comorbidities rates. Methods. This study was a retrospective, population-based cohort using linked administrative data from AS who were (n = 1791) matched comparison group 8955). Mortality for obtained Western Australia Death Register. The presence EAMs identified hospital records. compared between 2 groups Cox proportional hazard models...

10.3899/jrheum.210909 article EN The Journal of Rheumatology 2022-04-15

Objectives To investigate the current demographic, clinical and histological characteristics of patients with lupus nephritis (LN) in Western Australia (WA) regards to their predictive value for patient renal outcome. Methods Retrospective study adult systemic erythematosus (SLE) a first biopsy demonstrating LN between 1997 2017 at metropolitan tertiary hospital WA. Clinical data were collected baseline last follow-up findings classified by International Society Nephrology (ISN) criteria....

10.1177/0961203318792361 article EN Lupus 2018-08-09

Abstract Objective To assess the burden of subclinical intra‐articular inflammation using ultrasound in people with gout. Methods A pilot, prospective longitudinal cohort 28 participants gout were examined twice, once during a flare (n = 25) and then an inter‐critical phase 27). At each visit, 52 joint count was done followed by examination for detection power Doppler (PD) signal. Clinically active joints defined as tender swollen. Data collected on patient reported pain ‐ visual analog...

10.1111/1756-185x.13811 article EN International Journal of Rheumatic Diseases 2020-02-27

Mortality rates for patients with SLE have not been reported in Australia. This study determined the association between a hospitalisation mortality.Population-level cohort of (n=2112; 25 710 person-years) and general population comparators (controls) (n=21, 120; 280 637 identified from hospital records contained within WA Rheumatic Disease Epidemiological Registry 1980 to 2013. was by ICD-9-CM: 695.4, 710.0, ICD-10-AM: L93.0, M32.0. Controls were nearest matched (10:1) age, sex,...

10.1136/lupus-2021-000539 article EN cc-by-nc Lupus Science & Medicine 2021-10-01

Background Insulin growth factor-1 (IGF1) activates cell proliferation pathways and inhibits apoptosis. IGF1 is involved in tumour required for T-cell independent activation of B cells. Activated cells autoantibody production are a hallmark systemic lupus erythematosus (SLE). To investigate the possible role SLE, we studied across clinical characteristics, immunological biomarkers, disease activity organ damage SLE patients. Method In cross-sectional study, collected medication, (SLEDAI-2K)...

10.1177/0961203318756288 article EN Lupus 2018-01-31

von Willebrand factor (VWF) is involved in platelet plug formation and protein transport. Increased VWF levels systemic lupus erythematous (SLE) are considered risk factors for vascular events. levels, however, do not accurately reflect its platelet-aggregating function, which has been examined SLE.Cross-sectional study with clinical laboratory data obtained patients SLE (n=92) from a regional registry. function was determined by ristocetin-induced aggregation (VWF ristocetin cofactor,...

10.1136/lupus-2016-000162 article EN cc-by-nc Lupus Science & Medicine 2016-08-01

Abstract Aim Ankylosing spondylitis (AS) has been associated with a modest increase in the risk of cancer. However, little is known as to how AS influences mortality following cancer diagnosis. This study compared and subsequent patients non‐AS population group. Methods Patients diagnosed Western Australia (WA) between 1980 2014 were identified from WA Rheumatic Disease Epidemiological Register (N = 2152; 31 099 patient‐years). A comparison group 10 760; 165 609 patient‐years) was selected...

10.1111/1756-185x.14036 article EN International Journal of Rheumatic Diseases 2020-11-30

We compared survival and causes of death in Western Australian (WA) ANCA-associated vasculitis (AAV) PAN patients with controls the WA population.In this data linkage study, we identified incident AAV/PAN age, sex temporally matched 1980-2014 from Rheumatic Disease Epidemiological Registry. Survival analyses time-varying were performed.Six hundred fourteen 6672 controls; 229 died over 5277 person-years follow-up 1009 73835 person-years. was reduced [hazard ratio (HR) 3.5 (95% CI: 3.1, 4.1)],...

10.1093/rheumatology/keab469 article EN Lara D. Veeken 2021-06-11

To describe the incidence, risk factors and long-term outcomes in children hospitalised with septic arthritis (SA) Western Australia (WA). We extracted state-wide longitudinally linked administrative health data for patients aged < 16 years a first diagnostic code of 711.X (ICD9-CM) M00.X (ICD10-AM) WA period 1990–2010. Annual incidence rates (AIR) per 100,000 95% confidence intervals (CIs), prior conditions during median lookback 63.2 [interquartile range (IQR) 19.8–117.1] months outcomes,...

10.1007/s40744-021-00307-x article EN cc-by-nc Rheumatology and Therapy 2021-04-25

To explore the association between systemic lupus erythematosus (SLE) with risk of cancer development and subsequent 5-year mortality in Western Australia (WA).Population-level, data linkage study SLE patients (n = 2111) general population comparators 21 110) hospitalized 1980 2014. (identified by ICD-9-CM: 695.4, 710.0, ICD-10-AM: L93.0, M32.0) were nearest matched (10:1) for age, sex, Aboriginality, temporality. Follow up was from time zero (index hospitalization) to development, death or...

10.1111/1756-185x.14784 article EN cc-by International Journal of Rheumatic Diseases 2023-06-20

While it is a common practice to monitor complement levels in patients with systemic lupus erythematosus aid flare prediction and detection, unclear if this strategy helpful preventing subsequent organ damage. We studied longitudinal 102 SLE during median follow-up of 13.8 years (IQR 7.0, 23.1). Low was defined as C3 &lt; 0.84 g/L and/or C4 0.08 g/L, disease activity by clinical SLEDAI-2K, damage SLICC-DI. calculated time averaged SLEDAI score (cWAS) performed multivariate regression models...

10.1155/2018/8051972 article EN cc-by Journal of Immunology Research 2018-12-30
Coming Soon ...